Exalenz Bioscience Price to Sales vs. Current Asset Fundamental AnalysisExalenz Bioscience Ltd is one of the top stocks in current asset category among related companies. It is rated # 2 in price to sales category among related companies . The ratio of Current Asset to Price to Sales for Exalenz Bioscience Ltd is about 1,982,851 Current Asset is all of company's assets that can be used to pay off current liabilities within current fiscal period or over next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets, since these assets can be easily liquidated in case the company goes bankrupt. However it is usually not enough to know if a company is in a good shape just based on current asset alone; the amount of current liabilities should always be considered.Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
The most important factor to remember is that the price of equity takes a firm's debt into account, whereas the sales does not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
Exalenz Bioscience Price to Sales Comparison